From Wikipedia, the free encyclopedia
Jump to: navigation, search
Frovatriptan 2.png
Systematic (IUPAC) name
Clinical data
Trade names Frova
AHFS/ monograph
MedlinePlus a604013
  • AU: B3
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability 20–30%
Metabolism Hepatic
Half-life 26 hours
Excretion Renal
158930-17-7 N
PubChem CID 77992
DrugBank DB00998 YesY
ChemSpider 70378 YesY
KEGG D07997 N
Synonyms 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
Chemical data
Formula C14H17N3O
243.304 g/mol
 N (what is this?)  (verify)

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]


Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

Mechanism of action[edit]

Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.

Adverse effects[edit]

Serious but rare cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.


Frovatriptan should not be given to patients with:

  • Ischemic heart disease
  • Cerebrovascular syndrome
  • Peripheral vascular disease
  • Uncontrolled hypertension
  • Hemiplegic or basilar migraine

US licensing[edit]

Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006,[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).


  1. ^ "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28. 
  2. ^ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28. 

External links[edit]